Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133


Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.

Somers K, Kosciolek A, Bongers A, El-Ayoubi A, Karsa M, Mayoh C, Wadham C, Middlemiss S, Neznanov N, Kees UR, Lock RB, Gudkov A, Sutton R, Gurova K, Haber M, Norris MD, Henderson MJ.

Int J Cancer. 2019 Jul 20. doi: 10.1002/ijc.32582. [Epub ahead of print]


Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.

Cheung LC, Cruickshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS.

Haematologica. 2019 Jul;104(7):e300-e303. doi: 10.3324/haematol.2018.192906. Epub 2019 Jan 24. No abstract available.


A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.

Somers K, Wen VW, Middlemiss SMC, Osborne B, Forgham H, Jung M, Karsa M, Clifton M, Bongers A, Gao J, Mayoh C, Raoufi-Rad N, Kusnadi EP, Hannan KM, Scott DA, Kwek A, Liu B, Flemming C, Chudakova DA, Pandher R, Failes TW, Lim J, Angeli A, Osterman AL, Imamura T, Kees UR, Supuran CT, Pearson RB, Hannan RD, Davis TP, McCarroll J, Kavallaris M, Turner N, Gudkov AV, Haber M, Norris MD, Henderson MJ.

Oncogene. 2019 May;38(20):3824-3842. doi: 10.1038/s41388-018-0666-5. Epub 2019 Jan 22.


New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.

Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, Oommen J, Wells JE, He B, Singh S, Chua GA, Ford J, Mullighan CG, Kotecha RS, Kees UR.

Leukemia. 2018 Nov;32(11):2326-2338. doi: 10.1038/s41375-018-0144-7. Epub 2018 May 8.


Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.

Stirnweiss A, Oommen J, Kotecha RS, Kees UR, Beesley AH.

Oncotarget. 2017 Dec 2;8(68):112313-112329. doi: 10.18632/oncotarget.22862. eCollection 2017 Dec 22.


Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.

Fransecky L, Neumann M, Heesch S, Schlee C, Ortiz-Tanchez J, Heller S, Mossner M, Schwartz S, Mochmann LH, Isaakidis K, Bastian L, Kees UR, Herold T, Spiekermann K, Gökbuget N, Baldus CD.

J Hematol Oncol. 2016 Sep 22;9(1):95.


Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.

Yadav BD, Samuels AL, Wells JE, Sutton R, Venn NC, Bendak K, Anderson D, Marshall GM, Cole CH, Beesley AH, Kees UR, Lock RB.

Oncotarget. 2016 Sep 13;7(37):58728-42. doi: 10.18632/oncotarget.11233.


Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.

Cruickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, Failes TW, Arndt GM, Smithers N, Prinjha RK, Anderson D, Carter KW, Gout AM, Lassmann T, O'Reilly J, Cole CH, Kotecha RS, Kees UR.

Leukemia. 2017 Jan;31(1):40-50. doi: 10.1038/leu.2016.165. Epub 2016 Jun 13.


CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.

Somers K, Chudakova DA, Middlemiss SM, Wen VW, Clifton M, Kwek A, Liu B, Mayoh C, Bongers A, Karsa M, Pan S, Cruikshank S, Scandlyn M, Hoang W, Imamura T, Kees UR, Gudkov AV, Chernova OB, Haber M, Norris MD, Henderson MJ.

Oncotarget. 2016 Jul 19;7(29):46067-46087. doi: 10.18632/oncotarget.10022.


High expression of connective tissue growth factor accelerates dissemination of leukaemia.

Wells JE, Howlett M, Halse HM, Heng J, Ford J, Cheung LC, Samuels AL, Crook M, Charles AK, Cole CH, Kees UR.

Oncogene. 2016 Sep 1;35(35):4591-600. doi: 10.1038/onc.2015.525. Epub 2016 Jan 25.


A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma.

Stirnweiss A, McCarthy K, Oommen J, Crook ML, Hardy K, Kees UR, Wilton SD, Anazodo A, Beesley AH.

Oncogenesis. 2015 Nov 9;4:e174. doi: 10.1038/oncsis.2015.33.


Novel CT domain-encoding splice forms of CTGF/CCN2 are expressed in B-lineage acute lymphoblastic leukaemia.

Welch MD, Howlett M, Halse HM, Greene WK, Kees UR.

Leuk Res. 2015 Aug;39(8):913-20. doi: 10.1016/j.leukres.2015.05.008. Epub 2015 May 22.


The role of CCN family genes in haematological malignancies.

Wells JE, Howlett M, Cheung LC, Kees UR.

J Cell Commun Signal. 2015 Sep;9(3):267-78. doi: 10.1007/s12079-015-0296-4. Epub 2015 May 31.


Rare childhood cancers--an increasing entity requiring the need for global consensus and collaboration.

Kotecha RS, Kees UR, Cole CH, Gottardo NG.

Cancer Med. 2015 Jun;4(6):819-24. doi: 10.1002/cam4.426. Epub 2015 Feb 9.


Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.

Richmond J, Carol H, Evans K, High L, Mendomo A, Robbins A, Meyer C, Venn NC, Marschalek R, Henderson M, Sutton R, Kurmasheva RT, Kees UR, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2015 Mar 15;21(6):1395-405. doi: 10.1158/1078-0432.CCR-14-2300. Epub 2015 Jan 8.


Gene expression analyses of the spatio-temporal relationships of human medulloblastoma subgroups during early human neurogenesis.

Hooper CM, Hawes SM, Kees UR, Gottardo NG, Dallas PB.

PLoS One. 2014 Nov 20;9(11):e112909. doi: 10.1371/journal.pone.0112909. eCollection 2014.


Aberrant expression of aldehyde dehydrogenase 1A (ALDH1A) subfamily genes in acute lymphoblastic leukaemia is a common feature of T-lineage tumours.

Longville BA, Anderson D, Welch MD, Kees UR, Greene WK.

Br J Haematol. 2015 Jan;168(2):246-57. doi: 10.1111/bjh.13120. Epub 2014 Sep 11.


A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.

Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR, Lock RB.

Blood Cancer J. 2014 Aug 1;4:e232. doi: 10.1038/bcj.2014.52.


Germ-line and somatic DICER1 mutations in pineoblastoma.

de Kock L, Sabbaghian N, Druker H, Weber E, Hamel N, Miller S, Choong CS, Gottardo NG, Kees UR, Rednam SP, van Hest LP, Jongmans MC, Jhangiani S, Lupski JR, Zacharin M, Bouron-Dal Soglio D, Huang A, Priest JR, Perry A, Mueller S, Albrecht S, Malkin D, Grundy RG, Foulkes WD.

Acta Neuropathol. 2014 Oct;128(4):583-95. doi: 10.1007/s00401-014-1318-7. Epub 2014 Jul 15.


Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer.

Wells JE, Howlett M, Cole CH, Kees UR.

Int J Cancer. 2015 Aug 1;137(3):504-11. doi: 10.1002/ijc.28972. Epub 2014 May 30. Review.


The evolution of clinical trials for infant acute lymphoblastic leukemia.

Kotecha RS, Gottardo NG, Kees UR, Cole CH.

Blood Cancer J. 2014 Apr 11;4:e200. doi: 10.1038/bcj.2014.17.


Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis.

Cheung LC, Strickland DH, Howlett M, Ford J, Charles AK, Lyons KM, Brigstock DR, Goldschmeding R, Cole CH, Alexander WS, Kees UR.

Haematologica. 2014 Jul;99(7):1149-56. doi: 10.3324/haematol.2013.102327. Epub 2014 Apr 11.


Comparative drug screening in NUT midline carcinoma.

Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW, Arndt GM, Charles AK, Cole CH, Kees UR.

Br J Cancer. 2014 Mar 4;110(5):1189-98. doi: 10.1038/bjc.2014.54. Epub 2014 Feb 11.


Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia.

Samuels AL, Heng JY, Beesley AH, Kees UR.

Br J Haematol. 2014 Apr;165(1):57-66. doi: 10.1111/bjh.12727. Epub 2014 Jan 23.


Hypomethylation of the CTGF gene locus is a common feature of paediatric pre-B acute lymphoblastic leukaemia.

Welch MD, Greene WK, Kees UR.

Br J Haematol. 2013 Aug;162(4):537-41. doi: 10.1111/bjh.12417. Epub 2013 Jun 15.


Drug-gene modeling in pediatric T-cell acute lymphoblastic leukemia highlights importance of 6-mercaptopurine for outcome.

Beesley AH, Firth MJ, Anderson D, Samuels AL, Ford J, Kees UR.

Cancer Res. 2013 May 1;73(9):2749-59. doi: 10.1158/0008-5472.CAN-12-3852. Epub 2013 Feb 22.


Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.

Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, Kees UR, Beesley AH.

Oncogene. 2013 Sep 26;32(39):4664-74. doi: 10.1038/onc.2012.487. Epub 2012 Nov 5.


FusionFinder: a software tool to identify expressed gene fusion candidates from RNA-Seq data.

Francis RW, Thompson-Wicking K, Carter KW, Anderson D, Kees UR, Beesley AH.

PLoS One. 2012;7(6):e39987. doi: 10.1371/journal.pone.0039987. Epub 2012 Jun 27.


Molecular characterization of identical, novel MLL-EPS15 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia.

Kotecha RS, Ford J, Beesley AH, Anderson D, Cole CH, Kees UR.

Haematologica. 2012 Sep;97(9):1447-50. doi: 10.3324/haematol.2012.065730. Epub 2012 May 11. No abstract available.


Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.

Tesfai Y, Ford J, Carter KW, Firth MJ, O'Leary RA, Gottardo NG, Cole C, Kees UR.

Leuk Res. 2012 Mar;36(3):299-306. doi: 10.1016/j.leukres.2011.08.001. Epub 2011 Sep 1.


MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Gamble LD, Kees UR, Tweddle DA, Lunec J.

Oncogene. 2012 Feb 9;31(6):752-63. doi: 10.1038/onc.2011.270. Epub 2011 Jul 4.


Novel non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13) activating LMO2 by juxtaposition with MBNL1 and STAG2.

Chen S, Nagel S, Schneider B, Kaufmann M, Meyer C, Zaborski M, Kees UR, Drexler HG, MacLeod RA.

Leukemia. 2011 Oct;25(10):1632-5. doi: 10.1038/leu.2011.119. Epub 2011 Jun 7. No abstract available.


Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.

Beesley AH, Rampellini JL, Palmer ML, Heng JY, Samuels AL, Firth MJ, Ford J, Kees UR.

Mol Cancer. 2010 Oct 28;9:284. doi: 10.1186/1476-4598-9-284.


Silencing of TESTIN by dense biallelic promoter methylation is the most common molecular event in childhood acute lymphoblastic leukaemia.

Weeks RJ, Kees UR, Song S, Morison IM.

Mol Cancer. 2010 Jun 24;9:163. doi: 10.1186/1476-4598-9-163.


Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.

Cleaver AL, Beesley AH, Firth MJ, Sturges NC, O'Leary RA, Hunger SP, Baker DL, Kees UR.

Mol Cancer. 2010 May 12;9:105. doi: 10.1186/1476-4598-9-105.


Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.

Samuels AL, Peeva VK, Papa RA, Firth MJ, Francis RW, Beesley AH, Lock RB, Kees UR.

BMC Genomics. 2010 Apr 21;11:256. doi: 10.1186/1471-2164-11-256.


Effective adenovirus-mediated gene transfer into neural stem cells derived from human embryonic stem cells.

Bertram CM, Hawes SM, Egli S, Peh SL, Dottori M, Kees UR, Dallas PB.

Stem Cells Dev. 2010 Apr;19(4):569-78. doi: 10.1089/scd.2009.0183.


MEIS proteins as partners of the TLX1/HOX11 oncoprotein.

Milech N, Gottardo NG, Ford J, D'Souza D, Greene WK, Kees UR, Watt PM.

Leuk Res. 2010 Mar;34(3):358-63. doi: 10.1016/j.leukres.2009.06.003. Epub 2009 Jun 25.


Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.

Beesley AH, Firth MJ, Ford J, Weller RE, Freitas JR, Perera KU, Kees UR.

Br J Cancer. 2009 Jun 16;100(12):1926-36. doi: 10.1038/sj.bjc.6605072. Epub 2009 May 12. Erratum in: Br J Cancer. 2010 Mar 30;102(7):1200.


Classic and desmoplastic medulloblastoma: complete case reports and characterizations of two new cell lines.

Holthouse DJ, Dallas PB, Ford J, Fabian V, Murch AR, Watson M, Wong G, Bertram C, Egli S, Baker DL, Kees UR.

Neuropathology. 2009 Aug;29(4):398-409. doi: 10.1111/j.1440-1789.2008.00989.x. Epub 2008 Dec 11.


Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.

Beesley AH, Weller RE, Senanayake S, Welch M, Kees UR.

Leuk Res. 2009 Feb;33(2):321-5. doi: 10.1016/j.leukres.2008.08.007. Epub 2008 Sep 11.


The role of BSG (CD147) in acute lymphoblastic leukaemia and relapse.

Beesley AH, Weller RE, Kees UR.

Br J Haematol. 2008 Sep;142(6):1000-2. doi: 10.1111/j.1365-2141.2008.07296.x. Epub 2008 Jul 30. No abstract available.


Mechanism of relapse in pediatric acute lymphoblastic leukemia.

Henderson MJ, Choi S, Beesley AH, Sutton R, Venn NC, Marshall GM, Kees UR, Haber M, Norris MD.

Cell Cycle. 2008 May 15;7(10):1315-20. Epub 2008 Feb 29.


Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.

Hoffmann K, Firth MJ, Beesley AH, Freitas JR, Ford J, Senanayake S, de Klerk NH, Baker DL, Kees UR.

Br J Haematol. 2008 Mar;140(6):656-64. doi: 10.1111/j.1365-2141.2008.06981.x.


A xenograft model of infant leukaemia reveals a complex MLL translocation.

Henderson MJ, Choi S, Beesley AH, Baker DL, Wright D, Papa RA, Murch A, Campbell LJ, Lock RB, Norris MD, Haber M, Kees UR.

Br J Haematol. 2008 Mar;140(6):716-9. doi: 10.1111/j.1365-2141.2007.06966.x. Epub 2008 Jan 23. No abstract available.


Transcriptional regulation of FHL1 by TLX1/HOX11 is dosage, cell-type and promoter context-dependent.

Rice KL, Kees UR, Greene WK.

Biochem Biophys Res Commun. 2008 Mar 14;367(3):707-13. Epub 2007 Dec 10.


BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.

French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, Kutok JL, Toretsky JA, Tadavarthy AK, Kees UR, Fletcher JA, Aster JC.

Oncogene. 2008 Apr 3;27(15):2237-42. Epub 2007 Oct 15.


High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia.

Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, Brigstock DR, de Klerk NH, Kees UR.

Br J Haematol. 2007 Sep;138(6):740-8.


TLX1/HOX11 transcription factor inhibits differentiation and promotes a non-haemopoietic phenotype in murine bone marrow cells.

Dixon DN, Izon DJ, Dagger S, Callow MJ, Taplin RH, Kees UR, Greene WK.

Br J Haematol. 2007 Jul;138(1):54-67.


Supplemental Content

Support Center